Metoprolol tartrate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for metoprolol tartrate and what is the scope of freedom to operate?
Metoprolol tartrate
is the generic ingredient in two branded drugs marketed by Novartis, Am Regent, Baxter Hlthcare Corp, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Luitpold, Sandoz, Steriscience Speclts, Watson Labs, Validus Pharms, Alembic Pharms Ltd, Apothecon, Aurobindo Pharma, Chartwell Rx, Heritage Pharma, Ipca Labs Ltd, Mylan, Norvium Bioscience, Purepac Pharm, Renata, Rubicon, Sun Pharm Inds Inc, Sun Pharm Industries, Teva, Teva Pharms, Youngtech Pharms Inc, and Zydus Pharms, and is included in thirty-five NDAs. Additional information is available in the individual branded drug profile pages.There are twenty-seven drug master file entries for metoprolol tartrate. Fifty-six suppliers are listed for this compound.
Summary for metoprolol tartrate
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 30 |
NDAs: | 35 |
Drug Master File Entries: | 27 |
Finished Product Suppliers / Packagers: | 56 |
Raw Ingredient (Bulk) Api Vendors: | 109 |
Clinical Trials: | 25 |
Patent Applications: | 2,392 |
Drug Prices: | Drug price trends for metoprolol tartrate |
Drug Sales Revenues: | Drug sales revenues for metoprolol tartrate |
What excipients (inactive ingredients) are in metoprolol tartrate? | metoprolol tartrate excipients list |
DailyMed Link: | metoprolol tartrate at DailyMed |
Recent Clinical Trials for metoprolol tartrate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Consorcio Centro de Investigación Biomédica en Red (CIBER) | Phase 3 |
Instituto de Salud Carlos III | Phase 3 |
European Commission | Phase 3 |
Pharmacology for metoprolol tartrate
Drug Class | beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic beta-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for metoprolol tartrate
US Patents and Regulatory Information for metoprolol tartrate
Expired US Patents for metoprolol tartrate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | LOPRESSOR | metoprolol tartrate | INJECTABLE;INJECTION | 018704-001 | Mar 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Validus Pharms | LOPRESSOR | metoprolol tartrate | TABLET;ORAL | 017963-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Validus Pharms | LOPRESSOR | metoprolol tartrate | TABLET;ORAL | 017963-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Validus Pharms | LOPRESSOR | metoprolol tartrate | TABLET;ORAL | 017963-002 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Validus Pharms | LOPRESSOR | metoprolol tartrate | TABLET;ORAL | 017963-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | LOPRESSOR | metoprolol tartrate | INJECTABLE;INJECTION | 018704-001 | Mar 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.